Roivant Sciences Ltd. (ROIV)
Roivant Sciences Statistics
Share Statistics
Roivant Sciences has 713.55M shares outstanding. The number of shares has increased by -3.41% in one year.
| Shares Outstanding | 713.55M |
| Shares Change (YoY) | -3.41% |
| Shares Change (QoQ) | -1.98% |
| Owned by Institutions (%) | 77.82% |
| Shares Floating | 438.67M |
| Failed to Deliver (FTD) Shares | 331.06K |
| FTD / Avg. Volume | 5.33% |
Short Selling Information
The latest short interest is 45.1M, so 6.32% of the outstanding shares have been sold short.
| Short Interest | 45.1M |
| Short % of Shares Out | 6.32% |
| Short % of Float | 8.48% |
| Short Ratio (days to cover) | 5.47 |
Valuation Ratios
The PE ratio is 1.88 and the forward PE ratio is -9.32. Roivant Sciences's PEG ratio is 0.
| PE Ratio | 1.88 |
| Forward PE | -9.32 |
| PS Ratio | 65.46 |
| Forward PS | 3.8 |
| PB Ratio | 1.37 |
| P/FCF Ratio | -10.66 |
| PEG Ratio | 0 |
Enterprise Valuation
Roivant Sciences has an Enterprise Value (EV) of 2.13B.
| EV / Sales | 17.09 |
| EV / EBITDA | 0.49 |
| EV / EBIT | -2.79 |
| EV / FCF | -2.78 |
Financial Position
The company has a current ratio of 25.24, with a Debt / Equity ratio of 0.08.
| Current Ratio | 25.24 |
| Quick Ratio | 25.1 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | 0.12 |
| Debt / FCF | -0.65 |
| Interest Coverage | 121.97 |
Financial Efficiency
Return on Equity is 72.86% and Return on Invested Capital is 60.48%.
| Return on Equity | 72.86% |
| Return on Assets | 60.21% |
| Return on Invested Capital | 60.48% |
| Revenue Per Employee | $137.44K |
| Profits Per Employee | $4.79M |
| Employee Count | 908 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0.79 |
Taxes
| Income Tax | 22.22M |
| Effective Tax Rate | 0.52% |
Stock Price Statistics
The stock price has increased by -1.56% in the last 52 weeks. The beta is 1.25, so Roivant Sciences's price volatility has been higher than the market average.
| Beta | 1.25 |
| 52-Week Price Change | -1.56% |
| 50-Day Moving Average | 10.37 |
| 200-Day Moving Average | 11.25 |
| Relative Strength Index (RSI) | 59.34 |
| Average Volume (20 Days) | 6.21M |
Income Statement
In the last 12 months, Roivant Sciences had revenue of 124.8M and earned 4.35B in profits. Earnings per share was 5.55.
| Revenue | 124.8M |
| Gross Profit | 96.83M |
| Operating Income | 4.24B |
| Net Income | 4.35B |
| EBITDA | 4.31B |
| EBIT | 4.29B |
| Earnings Per Share (EPS) | 5.55 |
Balance Sheet
The company has 6.54B in cash and 499.75M in debt, giving a net cash position of 6.04B.
| Cash & Cash Equivalents | 6.54B |
| Total Debt | 499.75M |
| Net Cash | 6.04B |
| Retained Earnings | 576.17M |
| Total Assets | 5.79B |
| Working Capital | 5.22B |
Cash Flow
In the last 12 months, operating cash flow was -765.27M and capital expenditures -1.38M, giving a free cash flow of -766.65M.
| Operating Cash Flow | -765.27M |
| Capital Expenditures | -1.38M |
| Free Cash Flow | -766.65M |
| FCF Per Share | -0.98 |
Margins
Gross margin is 77.59%, with operating and profit margins of 3399.19% and 3484.86%.
| Gross Margin | 77.59% |
| Operating Margin | 3399.19% |
| Pretax Margin | 3408.33% |
| Profit Margin | 3484.86% |
| EBITDA Margin | 3453.86% |
| EBIT Margin | 3399.19% |
| FCF Margin | -614.33% |
Dividends & Yields
ROIV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 53.24% |
| FCF Yield | -9.38% |
Analyst Forecast
The average price target for ROIV is $18, which is 67.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $18 |
| Price Target Difference | 67.8% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | 21.13 |
| Piotroski F-Score | 4 |